LMTK2 and prostate adenocarcinoma: The data confirm that the risk genotype at the GWAS variant rs6465657 correlates with LMTK2 expression and that prostate adenocarcinoma samples expresses 68% less LMTK2 mRNA than BPH samples, providing strong evidence for the role of this gene in PCa progression.